Nexalin Technology (NXL) Competitors $1.22 -0.01 (-0.41%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NXL vs. NSPR, SRTS, INO, MLSS, VANI, CTCX, EDAP, HYPR, APYX, and ZYXIShould you be buying Nexalin Technology stock or one of its competitors? The main competitors of Nexalin Technology include InspireMD (NSPR), Sensus Healthcare (SRTS), Inovio Pharmaceuticals (INO), Milestone Scientific (MLSS), Vivani Medical (VANI), Carmell (CTCX), Edap Tms (EDAP), Hyperfine (HYPR), Apyx Medical (APYX), and Zynex (ZYXI). These companies are all part of the "medical equipment" industry. Nexalin Technology vs. Its Competitors InspireMD Sensus Healthcare Inovio Pharmaceuticals Milestone Scientific Vivani Medical Carmell Edap Tms Hyperfine Apyx Medical Zynex InspireMD (NYSE:NSPR) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation, community ranking and risk. Does the media prefer NSPR or NXL? In the previous week, InspireMD and InspireMD both had 1 articles in the media. Nexalin Technology's average media sentiment score of 1.89 beat InspireMD's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the news media. Company Overall Sentiment InspireMD Neutral Nexalin Technology Very Positive Do institutionals and insiders hold more shares of NSPR or NXL? 44.8% of InspireMD shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 34.1% of InspireMD shares are owned by company insiders. Comparatively, 24.0% of Nexalin Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better valuation and earnings, NSPR or NXL? Nexalin Technology has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInspireMD$7.03M10.90-$19.92M-$0.79-3.16Nexalin Technology$131.07K159.24-$4.65M-$0.83-1.46 Is NSPR or NXL more profitable? InspireMD has a net margin of -413.96% compared to Nexalin Technology's net margin of -3,407.98%. InspireMD's return on equity of -69.42% beat Nexalin Technology's return on equity.Company Net Margins Return on Equity Return on Assets InspireMD-413.96% -69.42% -57.68% Nexalin Technology -3,407.98%-187.59%-167.21% Which has more risk & volatility, NSPR or NXL? InspireMD has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4, suggesting that its stock price is 300% more volatile than the S&P 500. Do analysts rate NSPR or NXL? InspireMD currently has a consensus target price of $4.50, indicating a potential upside of 80.00%. Nexalin Technology has a consensus target price of $5.00, indicating a potential upside of 311.52%. Given Nexalin Technology's higher possible upside, analysts plainly believe Nexalin Technology is more favorable than InspireMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InspireMD 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Nexalin Technology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in NSPR or NXL? InspireMD received 3 more outperform votes than Nexalin Technology when rated by MarketBeat users. However, 50.00% of users gave Nexalin Technology an outperform vote while only 4.95% of users gave InspireMD an outperform vote. CompanyUnderperformOutperformInspireMDOutperform Votes54.95%Underperform Votes9695.05% Nexalin TechnologyOutperform Votes250.00% Underperform Votes250.00% SummaryInspireMD beats Nexalin Technology on 9 of the 16 factors compared between the two stocks. Get Nexalin Technology News Delivered to You Automatically Sign up to receive the latest news and ratings for NXL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NXL vs. The Competition Export to ExcelMetricNexalin TechnologyElectromedical equipment IndustryBusiness SectorNASDAQ ExchangeMarket Cap$20.87M$3.38B$14.25B$8.62BDividend YieldN/A1.75%2.60%4.18%P/E Ratio-1.9018.7733.9919.96Price / Sales159.24203.96321.96157.63Price / CashN/A44.0930.9334.64Price / Book2.833.885.444.69Net Income-$4.65M$94.03M$194.85M$248.14M7 Day Performance2.10%12.89%2.16%2.39%1 Month Performance-2.80%22.44%3.28%6.05%1 Year Performance94.52%34.81%23.78%13.60% Nexalin Technology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NXLNexalin Technology2.8456 of 5 stars$1.22-0.4%$5.00+311.5%+98.3%$20.87M$131.07K-1.903Positive NewsGap DownNSPRInspireMD2.0668 of 5 stars$2.54-0.8%$4.50+77.2%-8.6%$77.81M$7.03M-3.3950SRTSSensus Healthcare2.5043 of 5 stars$4.72-0.8%$11.67+147.2%-10.5%$77.62M$39.49M11.8040Positive NewsINOInovio Pharmaceuticals4.0807 of 5 stars$2.10+5.0%$9.75+364.3%-78.2%$77.02M$283.10K-0.66320Positive NewsMLSSMilestone Scientific2.3097 of 5 stars$0.95+2.4%$1.25+32.3%+22.1%$74.16M$8.61M-13.5030Short Interest ↑VANIVivani Medical2.6382 of 5 stars$1.23-2.4%$4.00+225.2%-27.0%$72.87MN/A-2.7320News CoverageCTCXCarmellN/A$3.30-11.8%N/A+19.9%$68.99M$32.84K0.0014News CoverageGap UpEDAPEdap Tms2.2947 of 5 stars$1.81+1.8%$8.50+369.0%-66.2%$67.77M$62.77M-2.79230Short Interest ↓Analyst RevisionHYPRHyperfine3.395 of 5 stars$0.85+41.1%$1.06+24.7%-7.0%$66.16M$11.73M-1.49190Positive NewsGap DownHigh Trading VolumeAPYXApyx Medical2.8738 of 5 stars$1.62+3.8%N/A+14.3%$61.23M$47.29M-1.95270Short Interest ↓ZYXIZynex3.0126 of 5 stars$2.02-13.7%$6.00+197.0%-78.0%$61.08M$172.40M13.47770Positive NewsHigh Trading Volume Related Companies and Tools Related Companies InspireMD Alternatives Sensus Healthcare Alternatives Inovio Pharmaceuticals Alternatives Milestone Scientific Alternatives Vivani Medical Alternatives Carmell Alternatives Edap Tms Alternatives Hyperfine Alternatives Apyx Medical Alternatives Zynex Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NXL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nexalin Technology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nexalin Technology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
